Who are Belantamab mafodotin lyophilized powder's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ELRANATAMAB, Elrexfio, Elrexfio, Bcmaxcd3, Blenrep, Elrantamab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/belantamab-mafodotin-lyophilized-powder.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Belantamab mafodotin lyophilized powder — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Belantamab mafodotin lyophilized powder (Belantamab mafodotin lyophilized powder) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody-drug conjugate. Area: Oncology.

phase 2 Monoclonal antibody-drug conjugate BCMA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Belantamab mafodotin lyophilized powder (Belantamab mafodotin lyophilized powder) — GlaxoSmithKline. Monoclonal antibody targeting BCMA

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Belantamab mafodotin lyophilized powder TARGET	Belantamab mafodotin lyophilized powder	GlaxoSmithKline	phase 2	Monoclonal antibody-drug conjugate	BCMA
ELRANATAMAB	ELRANATAMAB		marketed		BCMA, CD3	2023-01-01
Elrexfio	elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrexfio	Elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Bcmaxcd3	TECLISTAMAB	Johnson & Johnson	marketed		CD3, BCMA	2022-01-01
Blenrep	BELANTAMAB MAFODOTIN	GSK	marketed		BCMA	2020-01-01
Elrantamab	elrantamab	Pfizer	marketed	Bispecific Antibody	BCMA (B-cell maturation antigen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody-drug conjugate class)

GlaxoSmithKline · 2 drugs in this class
RemeGen Co., Ltd. · 2 drugs in this class
Copharos · 1 drug in this class
Eastern Cooperative Oncology Group · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Mirati Therapeutics Inc. · 1 drug in this class
NYU Langone Health · 1 drug in this class
The Lymphoma Academic Research Organisation · 1 drug in this class
Astellas Pharma Global Development, Inc. · 1 drug in this class
Yan Zhang, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Belantamab mafodotin lyophilized powder — Competitive Intelligence Brief. https://druglandscape.com/ci/belantamab-mafodotin-lyophilized-powder. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab